Amenorrhea natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 34: | Line 34: | ||
*Among patients of [[androgen insensitivity syndrome]] there is an increased risk of [[testicular cancer]], and surveillance is needed appropriate intervals. | *Among patients of [[androgen insensitivity syndrome]] there is an increased risk of [[testicular cancer]], and surveillance is needed appropriate intervals. | ||
*[[Prognosis]] of [[Polycystic ovary syndrome|polycystic ovary syndrome (PCOS)]] is generally good. Long term dietary management and [[exercise]] along with [[metformin]] therapy decreases the [[cardiovascular]] and [[pregnancy]] complications in the future.<ref name="pmid18007129">{{cite journal |vauthors=Hart R |title=Polycystic ovarian syndrome--prognosis and treatment outcomes |journal=Curr. Opin. Obstet. Gynecol. |volume=19 |issue=6 |pages=529–35 |year=2007 |pmid=18007129 |doi=10.1097/GCO.0b013e3282f10e22 |url=}}</ref> | *[[Prognosis]] of [[Polycystic ovary syndrome|polycystic ovary syndrome (PCOS)]] is generally good. Long term dietary management and [[exercise]] along with [[metformin]] therapy decreases the [[cardiovascular]] and [[pregnancy]] complications in the future.<ref name="pmid18007129">{{cite journal |vauthors=Hart R |title=Polycystic ovarian syndrome--prognosis and treatment outcomes |journal=Curr. Opin. Obstet. Gynecol. |volume=19 |issue=6 |pages=529–35 |year=2007 |pmid=18007129 |doi=10.1097/GCO.0b013e3282f10e22 |url=}}</ref> | ||
*[[Prognosis]] is excellent for hyperprolactinemia. Depending on the size of the [[tumor]] and the extent of [[tumor]] resection, the rate of recurrence may range from 20% to 50%. The majority of recurrent prolactinomas develop within the first 5 years.<ref>http://www.niddk.nih.gov/health-information/health-topics/endocrine/prolactinoma/Pages/fact-sheet.aspx</ref> | *[[Prognosis]] is excellent for hyperprolactinemia due to microprolactinoma. Depending on the size of the [[tumor]] and the extent of [[tumor]] resection, the rate of recurrence may range from 20% to 50%. The majority of recurrent prolactinomas develop within the first 5 years.<ref>http://www.niddk.nih.gov/health-information/health-topics/endocrine/prolactinoma/Pages/fact-sheet.aspx</ref> | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 13:37, 3 November 2017
|
Amenorrhea Microchapters |
|
Patient Information |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Amenorrhea natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Amenorrhea natural history, complications and prognosis |
|
FDA on Amenorrhea natural history, complications and prognosis |
|
CDC on Amenorrhea natural history, complications and prognosis |
|
Amenorrhea natural history, complications and prognosis in the news |
|
Blogs on Amenorrhea natural history, complications and prognosis |
|
Risk calculators and risk factors for Amenorrhea natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]
Overview
If left untreated, patients with amenorrhea may progress to develop infertility and osteoporosis. Common complications of amenorrhea are based on underlying disorder that induce amenorrhea. Prognosis is generally excellent and the mortality rate of patients with amenorrhea is approximately less than 1%, generally in patients with brain lesions.
Natural History, Complications, and Prognosis
Natural History
- If left untreated, all patients of amenorrhea may progress to develop infertility and osteoporosis.
- The majority of cases woth amenorrhea are result of four conditions, which include polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.
- Polycystic ovary syndrome (PCOS), if left untreated can lead to heart disease from elevated cholesterol and increased levels of androgens. Long periods of not having menstrual cycles leads to unopposed exposure of endometrium to estrogen, can result in endometrial cancer.[1]
- In functional (hypothalamic) amenorrhea, the patient usually reports normal regular cycles in the past, with sudden interruption of menstrual cycles for more than 3 months. There is almost always a history of weight loss (severe), excessive exercise, or drastic emotional stress prior to cessation of menstruation.[2]
- Premature ovarian failure presents with menopause before the age of 40 and elevated levels of gonadotropins. In the age group of 41 to 44 years, it is called pre-menopause. Patients of premature ovarian failure generally have a family history of ovarian failure.[3]
- Amenorrhea from hyperprolactinemia can be caused by prolactin overproduction or dopamine suppression, and is mostly seen in middle aged women.[4]
Complications
- Common complications of amenorrhea are based on the underlying disorder inducing amenorrhea. The majority of amenorrhea cases are caused by four conditions, which include polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.
- Common complications of amenorrhea from PCOS include:
- Hyperprolactinemia leads to galactorrhea, decreased libido, and pregnancy complications. In cases with prolactinoma, massive enlargement of the tumor may affect vision and pituitary function. It may also cause osteopenia and osteoporosis in pre-menopausal women.[5]
- Common complications of premature ovarian failure include infertility, osteoporosis, depression/anxiety, cardiac disease, and dementia.[6]
- Patients with hypothalamic (functional) amenorrhea experience various complications, such as infertility, decrease in bone mineral density (BMD), increased risk for fracture, along with cardiovascular and psychological complicatons.[2]
- The most important complication of premature ovarian failure is infertility, that is preventable to some extent with appropriate therapies. Bone loss and psychiatric disorders are other complications.[7]
Prognosis
- Prognosis is generally excellent and the mortality rate of patients with amenorrhea is approximately less than 1%.
- Among patients of androgen insensitivity syndrome there is an increased risk of testicular cancer, and surveillance is needed appropriate intervals.
- Prognosis of polycystic ovary syndrome (PCOS) is generally good. Long term dietary management and exercise along with metformin therapy decreases the cardiovascular and pregnancy complications in the future.[8]
- Prognosis is excellent for hyperprolactinemia due to microprolactinoma. Depending on the size of the tumor and the extent of tumor resection, the rate of recurrence may range from 20% to 50%. The majority of recurrent prolactinomas develop within the first 5 years.[9]
References
- ↑ Palomba S, Santagni S, Falbo A, La Sala GB (2015). "Complications and challenges associated with polycystic ovary syndrome: current perspectives". Int J Womens Health. 7: 745–63. doi:10.2147/IJWH.S70314. PMC 4527566. PMID 26261426.
- ↑ 2.0 2.1 Meczekalski B, Katulski K, Czyzyk A, Podfigurna-Stopa A, Maciejewska-Jeske M (2014) Functional hypothalamic amenorrhea and its influence on women's health. J Endocrinol Invest 37 (11):1049-56. DOI:10.1007/s40618-014-0169-3 PMID: 25201001
- ↑ Vegetti W, Marozzi A, Manfredini E, Testa G, Alagna F, Nicolosi A, Caliari I, Taborelli M, Tibiletti MG, Dalprà L, Crosignani PG (2000). "Premature ovarian failure". Mol. Cell. Endocrinol. 161 (1–2): 53–7. PMID 10773392.
- ↑ Mattei AM, Severini V, Crosignani PG (1991). "Natural history of hyperprolactinemia". Ann. N. Y. Acad. Sci. 626: 130–6. PMID 2058949.
- ↑ Sanfilippo JS (1999). "Implications of not treating hyperprolactinemia". J Reprod Med. 44 (12 Suppl): 1111–5. PMID 10649820.
- ↑ "Premature ovarian failure - Symptoms and causes - Mayo Clinic".
- ↑ Nelson LM (2009). "Clinical practice. Primary ovarian insufficiency". N Engl J Med. 360 (6): 606–14. doi:10.1056/NEJMcp0808697. PMC 2762081. PMID 19196677.
- ↑ Hart R (2007). "Polycystic ovarian syndrome--prognosis and treatment outcomes". Curr. Opin. Obstet. Gynecol. 19 (6): 529–35. doi:10.1097/GCO.0b013e3282f10e22. PMID 18007129.
- ↑ http://www.niddk.nih.gov/health-information/health-topics/endocrine/prolactinoma/Pages/fact-sheet.aspx